Is IRIDEX CORP financially healthy?

IRIDEX CORP scores 4 out of 8 on the Piotroski F-score. Only 8 of the nine tests could be computed from what it filed; the rest need a prior year it has not reported. Its Altman Z-score puts it in the distress zone. Every test and the numbers behind it are shown above, so the arithmetic is checkable rather than something you have to take on trust.

Who are the largest institutional holders of IRIDEX CORP?

Among the managers tracked here, the biggest positions as of the 2026-Q2 13F filings are RENAISSANCE TECHNOLOGIES LLC (adding), MORGAN STANLEY, GEODE CAPITAL MANAGEMENT, LLC (trimming). Direction is the change in share count against that manager's own previous filing; managers with no prior filing are left out rather than counted as new buyers.

IRIDEX CORP (IRIX)

Nasdaq · Common Stock · Electromedical & Electrotherapeutic Apparatus

One email a week from me: what it filed, which 13F holders added or cut, where its scores stand. Free.

Financial health

Two standard screens, computed from the XBRL in FY2026 against FY2024. Every test shows the numbers behind it — a score with its inputs hidden is a number you cannot check.

Piotroski F-score

4 / 8

FAILReturn on assets positiveROA -15.2%
FAILOperating cash flow positiveOCF -2M
PASSReturn on assets improving-30.6% → -15.2%
PASSCash flow exceeds earningsOCF -2M vs NI -4M
FAILLong-term debt ratio fallingno debt reported
PASSCurrent ratio improving1.42 → 1.91
FAILNo share dilution16M → 17M shares
FAILGross margin improving40.1% → 36.5%
PASSAsset turnover improving1.67× → 1.81×

Altman Z-score

-2.04distress

Bankruptcy-risk screen combining working capital, retained earnings, operating income, market value against liabilities, and asset turnover. Above 2.99 is the safe zone; below 1.81 is distress.

Cash conversion: 47.7%
Share count change: 3.0%

Six-year record

Year	Revenue	Net income	Free cash flow	Gross margin	Shares
FY2021	$36.3M	−$6.3M	−$3.3M	42.8%	13,842,000
FY2022	$53.9M	−$5.2M	$8.0M	42.4%	15,421,000
FY2022	$57.0M	−$7.5M	−$9.8M	44.5%	15,938,000
FY2023	$51.9M	−$9.6M	−$6.9M	42.0%	16,128,000
FY2024	$48.7M	−$8.9M	−$7.3M	40.1%	16,439,000
FY2026

Ownership flow

6 institutions tracked — 2 added, 1 reduced, 1 opened a new position. Active managers added 65,014 shares while index money cut 21,199.

Institutional holders of IRIDEX CORP and their share-count change
Manager	Kind	Shares	Change	Value
CITADEL ADVISORS LLC	Hedge fund	98,950	+38,099	$113,298
RENAISSANCE TECHNOLOGIES LLC	Hedge fund	423,542	+26,915	$484,958
GEODE CAPITAL MANAGEMENT, LLC	Index	138,960	−21,199	$159,153

MORGAN STANLEY holds a position with no prior filing to compare against, so its change is unknown rather than zero — and it is left out of the totals above.

From 13F filings, which cover institutions managing over $100m and are filed up to 45 days after the quarter ends — so this is a considered position, not a live one, and it is not the whole shareholder register.

Identity

CIK: 0001006045
FIGI: BBG000BZB346
SIC: 3845 · Electromedical & Electrotherapeutic Apparatus
Incorporated: DE
Headquarters: MOUNTAIN VIEW, CA

Ownership

Institutional: 19.5%
Institutions: 33
Insiders: 36.7%

Ownership percentages are a vendor aggregate, not a filing — unlike everything else on this page.

Questions about IRIDEX CORP

Is IRIDEX CORP financially healthy?: IRIDEX CORP scores 4 out of 8 on the Piotroski F-score. Only 8 of the nine tests could be computed from what it filed; the rest need a prior year it has not reported. Its Altman Z-score puts it in the distress zone. Every test and the numbers behind it are shown above, so the arithmetic is checkable rather than something you have to take on trust.
Who are the largest institutional holders of IRIDEX CORP?: Among the managers tracked here, the biggest positions as of the 2026-Q2 13F filings are RENAISSANCE TECHNOLOGIES LLC (adding), MORGAN STANLEY, GEODE CAPITAL MANAGEMENT, LLC (trimming). Direction is the change in share count against that manager's own previous filing; managers with no prior filing are left out rather than counted as new buyers.

This page is one panel of the terminal

The structure map above is the Corporate Blueprint, and in the desktop it is interactive — click any entity to re-centre the map on it and walk the ownership chain. It sits alongside the screener, the scorecard and the filings lab on one desk, on your machine.

Download the terminal See pricing

Sourced from SEC EDGAR primary filings. Figures are as reported by the company and are not investment advice. Scores are standard published screens computed from those filings; every input is shown above so you can check the arithmetic.